• Significant revenue growth and diversification since FY23
• Expanded addressable global market in clinical trials and medical imaging
• Focused on growth through more therapeutic areas, services, and customers

Resonance Health, an Australian healthcare technology and services company, presented its investor strategy day, highlighting significant revenue growth and diversification since FY23. The company has seen strong revenue growth of around 45% CAGR, reaching a guidance of ~$17M in FY26, with profitability of around $2M EBITDA. Resonance Health has expanded its addressable global market, now participating in various areas of the clinical trial ecosystem, including new imaging endpoints for metabolic and obesity conditions, as well as CRO and investigator site services. The company is operating in markets with strong tailwinds, both globally and in Australia, driven by factors such as technological breakthroughs, shortened development timeframes, and increased outsourcing of trials. Resonance Health's strategy focuses on getting a greater 'share of wallet' by expanding into more therapeutic areas, providing more services to each customer, and acquiring new customers through organic and inorganic growth. The company has also invested in technology, including the Resonance Bridge, to improve productivity and customer connectivity, while leveraging its deep domain expertise and reputation to resonate with customers. Resonance Health is well-positioned for growth, with a focus on automation, new endpoints, geographic expansion, and acquisitions to achieve its ambition of $50M in annual revenue by the end of FY28.

FY26 Guidance: Revenue ~$17M, Underlying EBITDA ~$2M. Target EBITDA margins over coming periods ~25% as operational leverage drives margin expansion. Operationally cashflow positive. Significant potential upside from conservative assumptions.

Resonance Health is focused on driving growth through more devices to existing and new customers, expanding into new therapeutic areas, and growing its TrialsWest and Resonance Clinical businesses through geographic and service expansion, both organically and through acquisitions.